FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $106,396 | -59.1% | 50,187 | -8.1% | 0.00% | -66.7% |
| Q2 2023 | $259,948 | +86839.1% | 54,611 | +4.2% | 0.00% | -40.0% |
| Q1 2023 | $299 | -43.9% | 52,434 | -0.7% | 0.01% | -54.5% |
| Q4 2022 | $533 | -99.9% | 52,784 | +12.3% | 0.01% | -52.2% |
| Q3 2022 | $1,053,000 | +15.7% | 46,999 | +28.0% | 0.02% | -4.2% |
| Q2 2022 | $910,000 | +55.3% | 36,715 | +142.9% | 0.02% | +71.4% |
| Q1 2022 | $586,000 | -70.1% | 15,114 | -54.9% | 0.01% | -57.6% |
| Q4 2021 | $1,961,000 | +567.0% | 33,515 | +841.4% | 0.03% | +450.0% |
| Q1 2021 | $294,000 | -82.5% | 3,560 | -91.5% | 0.01% | -91.8% |
| Q3 2020 | $1,680,000 | +29.8% | 42,035 | +11.5% | 0.07% | +14.1% |
| Q2 2020 | $1,294,000 | +79.2% | 37,710 | -18.9% | 0.06% | +156.0% |
| Q3 2019 | $722,000 | – | 46,484 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |